Recommended Phase 2 Dose for Abemaciclib in Combination With Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results From Study JPCS Part B
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Background Cyclin‐dependent kinase 4/6 (CDK4/6) pathway aberrations, including CDK4 or CCND1 amplification, CDKN2A/B loss, retinoblastoma (RB) dysregulation, and cyclin D overexpression, are relevant for pediatric cancers. Abemaciclib, a selective CDK4/6 inhibitor with preferential CDK4 activity and central nervous system (CNS) penetration, induces sustained G1 arrest. Preclinical pediatric models show additive or synergistic activity with temozolomide, supporting further evaluation. Here, the recommended Phase 2 dose (RP2D) for abemaciclib with temozolomide is defined in children and young adults with relapsed/refractory solid tumors. Procedure JPCS Part B was an open‐label, multicenter Phase 1b study using a 3 + 3 design to evaluate continuous abemaciclib (70–115 mg/m 2 orally BID) with temozolomide (100–150 mg/m 2 orally days 1–5) in 21‐day cycles. The primary objective was RP2D determination based on dose‐limiting toxicities (DLTs) and pharmacokinetics. Secondary objectives included safety and antitumor activity. Results Twenty‐six patients (median age 11 years; range, 1–18) with heavily pretreated relapsed/refractory tumors were enrolled. The RP2D was established as 115 mg/m 2 abemaciclib BID on Days 1–21, with 150 mg/m 2 temozolomide on Days 1–5 of 21‐day cycles, based on two DLTs (thrombocytopenia), one at the RP2D. The maximum tolerated dose was not reached. Toxicities reflected expected myelosuppression and predominantly low‐grade gastrointestinal events. Together, 35% and 19% of patients experienced Grades 3 and 4 treatment‐related toxicities, respectively. Steady‐state abemaciclib concentrations aligned with adult efficacy‐associated ranges, with no drug‐drug interactions. Three patients (12%) achieved partial responses and 10 (38%) stable disease, yielding 50% disease control. Three patients had sustained disease control with >6 months on treatment. Conclusions Abemaciclib plus temozolomide is feasible and well‐tolerated and shows preliminary antitumor activity, supporting further evaluation in Phase 2 trials. Trial Registration NCT04238819.
Source: Pediatric Blood & Cancer
Authors: Alvaro Lassaletta(Formal analysis, Investigation, Validation, Writing – original draft), Lucas Moreno(Methodology, Validation, Writing – original draft, Writing – review & editing), Ayumu Arakawa(Validation, Writing – review & editing), Anne Thorwarth(Investigation, Validation, Writing – review & editing), Antonio Ruggiero(Investigation, Writing – review & editing), Lindsey Hoffman(Investigation, Writing – review & editing), Amanda Sykes(Formal analysis, Validation, Visualization, Writing – original draft, Writing – review & editing), Yanhong Zhou(Conceptualization, Formal analysis, Methodology, Validation, Writing – original draft, Writing – review & editing), Sarah Nabinger(Methodology, Validation, Writing – original draft, Writing – review & editing), Holly Knoderer(Conceptualization, Methodology, Validation, Writing – original draft, Writing – review & editing), Antonio Juan Ribelles(Investigation, Writing – review & editing)
Institutions: Hospital Infantil Universitario Niño Jesús, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Institut d'Investigació Sanitària Acreditat Institut de Recerca - Hospital Universitari Vall d'Hebron, National Cancer Center Hospital, Charité – Universitätsmedizin Berlin, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Phoenix Children's Hospital, Eli Lilly (United States), Hospital Universitari i Politècnic La Fe
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,640
Funder: Eli Lilly and Company
OpenAlex ID: W7236156656
